Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mitsui Norin Co. Ltd. currently manages 1 pending office action within its patent portfolio. This 1 action is assigned to 1 distinct examiner, indicating a concentrated prosecution focus at this stage. BURKETT, DANIEL JOHN is identified as the busiest examiner for the company, currently overseeing 1 pending action. This distribution suggests that the company's immediate legal attention is focused on 1 point of contact within the patent office.
The current state of prosecution allows for a dedicated response strategy to this specific examiner's requirements. By addressing the concerns of a single individual, the company can streamline its advocacy efforts. This focused approach minimizes the administrative burden of managing multiple examiner relationships simultaneously.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKETT, DANIEL JOHN | 1 | 64.1% | +33.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18835840 | CANCER-CELL PROLIFERATION INHIBITOR AND CANCER-CELL-PROLIFERATION INHIBITION ENHANCER | BURKETT, DANIEL JOHN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18835840 | CANCER-CELL PROLIFERATION INHIBITOR AND CANCER-CELL-PROLIFERATION INHIBITION ENHANCER | BURKETT, DANIEL JOHN | 1624 | §112 | Final Rejection | — | Pending | Aug 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMitsui Norin Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Daniel John Burkett has the most, with 1 of Mitsui Norin Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.